Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
12 Jun 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214934
28 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250528703755/en/Nexus-Wins-Patent-Litigation-for-Injectable-Cyclophosphamide-Paving-Way-for-Generic
22 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250522266031/en/Nexus-Pharmaceuticals-Launches-Methylene-Blue-Injection
11 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250410021009/en/Nexus-Pharmaceuticals-Launches-Baclofen-Injection-Refill-Kit
31 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250331365849/en/Nexus-Pharmaceuticals-Launches-Fluorescein-2-mL
19 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250319933999/en/Nexus-Pharmaceuticals-Launches-Tranexamic-Acid
Details:
Methylene blue is a monoamine oxidase inhibitor, indicated for the treatment of methemoglobinemia.
Lead Product(s): Methylene Blue
Therapeutic Area: Hematology Brand Name: Methylene Blue-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 22, 2025
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Launches Methylene Blue Injection
Details : Methylene blue is a monoamine oxidase inhibitor, indicated for the treatment of methemoglobinemia.
Product Name : Methylene Blue-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2025
Details:
Tranexamic Acid in Sodium Chloride Injection is an antifibrinolytic indicated in patients with hemophilia for shortterm use to reduce or prevent hemorrhage.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Genetic Disease Brand Name: Tranexamic Acid Sodium Chloride Injection
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2025
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Launches Tranexamic Acid
Details : Tranexamic Acid in Sodium Chloride Injection is an antifibrinolytic indicated in patients with hemophilia for shortterm use to reduce or prevent hemorrhage.
Product Name : Tranexamic Acid Sodium Chloride Injection
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2025
Details:
Tacrolimus is a macrolide antibiotic with immunosuppressive properties, binds to FK506 binding protein inhibiting calcineurin phosphatase, received approval for organ rejection.
Lead Product(s): Tacrolimus
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 13, 2025
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Receives FDA Approval for Tacrolimus Injection
Details : Tacrolimus is a macrolide antibiotic with immunosuppressive properties, binds to FK506 binding protein inhibiting calcineurin phosphatase, received approval for organ rejection.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 13, 2025
Details:
The US FDA approved Methylene Blue Injection, USP (methylene blue). It is an oxidation-reduction agent that offers treatment of acquired methemoglobinemia.
Lead Product(s): Methylene Blue
Therapeutic Area: Hematology Brand Name: Methylene Blue Injection, USP
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 26, 2024
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Receives FDA Approval for Methylene Blue Injection, USP
Details : The US FDA approved Methylene Blue Injection, USP (methylene blue). It is an oxidation-reduction agent that offers treatment of acquired methemoglobinemia.
Product Name : Methylene Blue Injection, USP
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 26, 2024
Details:
Baclofen is a GABA-ergic agonist. It is indicated for treatment of patients with multiple sclerosis, cerebral palsy, spinal cord injuries, and other conditions that result in muscle spasms.
Lead Product(s): Baclofen
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2024
Lead Product(s) : Baclofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Launches Baclofen Injection, USP
Details : Baclofen is a GABA-ergic agonist. It is indicated for treatment of patients with multiple sclerosis, cerebral palsy, spinal cord injuries, and other conditions that result in muscle spasms.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2024
Details:
Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.
Lead Product(s): Tirofiban
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tirofiban Hydrochloride-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 02, 2023
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection
Details : Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.
Product Name : Tirofiban Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2023
Details:
Potassium Chloride Injection is a sterile, nonpyrogenic, highly concentrated, ready-to-use, which is indicated in the treatment of potassium deficiency states when oral replacement is not feasible.
Lead Product(s): Potassium Chloride
Therapeutic Area: Nutrition and Weight Loss Brand Name: Potassium Chloride-Generic
Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 15, 2023
Lead Product(s) : Potassium Chloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Receives FDA Approval for Potassium Chloride for Injection Concentrate, USP
Details : Potassium Chloride Injection is a sterile, nonpyrogenic, highly concentrated, ready-to-use, which is indicated in the treatment of potassium deficiency states when oral replacement is not feasible.
Product Name : Potassium Chloride-Generic
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 15, 2023
Details:
Emerphed (ephedrine sulfate) is a sympathomimetic amine, an agonist at alpha- and beta-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons.
Lead Product(s): Ephedrine Sulfate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Emerphed
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 03, 2023
Lead Product(s) : Ephedrine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals, Inc. Receives FDA Approval for EMERPHED® (ephedrine sulfate injection) Pre...
Details : Emerphed (ephedrine sulfate) is a sympathomimetic amine, an agonist at alpha- and beta-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons.
Product Name : Emerphed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2023
Details:
Erythromycin Lactobionate for Injection, USP is indicated in treatment of infections caused by susceptible strains of designated organisms when oral administration is not possible or when severity of infection requires immediate high serum levels of erythromycin.
Lead Product(s): Erythromycin Lactobionate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Erythromycin Lactobionate-Generic
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 21, 2022
Lead Product(s) : Erythromycin Lactobionate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Announces Launch of Erythromycin Lactobionate for Injection, USP
Details : Erythromycin Lactobionate for Injection, USP is indicated in treatment of infections caused by susceptible strains of designated organisms when oral administration is not possible or when severity of infection requires immediate high serum levels of eryt...
Product Name : Erythromycin Lactobionate-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 21, 2022
Details:
Erythromycin Lactobionate for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible.
Lead Product(s): Erythromycin Lactobionate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Erythromycin Lactobionate-Generic
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 17, 2022
Lead Product(s) : Erythromycin Lactobionate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Inc. Receives FDA Approval of Erythromycin
Details : Erythromycin Lactobionate for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible.
Product Name : Erythromycin Lactobionate-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 17, 2022
ABOUT THIS PAGE